H3K18laは,卵巣がんにおけるフェロプトーシスとシスプラチン治療に対する感受性を抑制し,STILのTRA2A媒介による代替スプライシングを促進する

Mingyang Gao¹, Shiming Wang², Zhiyuan Huang³

¹General Hospital of Northern Theater Command, Shenyang, China.

Cancer research and treatment

|September 4, 2025

まとめ

卵巣がん細胞はヒストンの乳化によって誘発されるTRA2A-STIL信号経路を通じて細胞死を回避する. この経路をターゲットにすることで化学療法の効果が向上し卵巣がんの新たな治療戦略が生まれます

科学分野:

腫瘍学
分子生物学
エピジェネティクス

背景:

卵巣がん (OC) は,診断が遅れており,化学抵抗性があるため,大きな課題となっています.
OCの開発メカニズムを理解し,新しい治療目標を特定することは極めて重要です.

研究の目的:

TRA2Aとヒストンの乳化がOC進行における役割を明らかにする.
OCの化学抵抗を克服するための新しい治療標的を特定する.

主な方法:

バイオ情報分析,qRT-PCR,Western Blot (WB),およびTRA2Aとヒストンの乳化に対する免疫ヒストロケミストリー (IHC).
細胞増殖検査 (CCK8,クローン形成,EDU) とトランスウェル検査
裸のマウスの異種移植モデルを用いた代替スプライシング分析と in vivo 検証のためのRT-PCR

主要な成果:

TRA2A- STILシグナリング軸経由でのOCフェロプトーシス回避の新しいメカニズムが特定されました.
ヒストン乳化 (H3K18la) はTRA2Aの転写を促進し,STIL mRNAの代替スプライシングとSTIL-L同型を生成する.
シスプラチンとの併用による標的型TRA2Aノックダウンは,OC治療の有効性を高めました.

結論:

OC細胞は,H3K18la-改変されたTRA2A-STIL信号軸を通してフェロプトーシスを回避する.
TRA2A媒介による代替スプライシングをターゲットにすることで,卵巣がんに対する有望な治療戦略を示しています.

キーワード:

代替スプライシングフェロプトーシス H3K18la 卵巣腫瘍トラ2A

さらに関連する動画

11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

8.3K

09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

関連する概念動画

02:18

Alternative RNA Splicing

21.7K

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

21.7K

01:32

RNA Splicing

56.9K

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

56.9K

02:39

lncRNA - Long Non-coding RNAs

8.9K

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

8.9K

02:41

Chromatin Structure Regulates pre-mRNA Processing

7.2K

In eukaryotic cells, nascent mRNA transcripts need to undergo many post-transcriptional modifications to reach the cell cytoplasm and translate into functional proteins. For a long time, transcription and pre-mRNA processing were considered two independent events that occur sequentially in the cell. However, it has now been well established that transcription and pre-mRNA processing are two simultaneous processes that are precisely regulated inside the cell.
The chromatin structure, especially...

7.2K

01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.9K

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

7.9K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...